{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T02:19:33Z","timestamp":1755224373280,"version":"3.43.0"},"reference-count":10,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2025,8,12]]},"abstract":"<jats:p>A woman with no significant medical history had 3 days of headache, fatigue, and expressive aphasia; laboratory testing showed microangiopathic hemolytic anemia, increasing schistocytes on serial blood smears, diminished ADAMTS13 activity, and a high inhibitor titer. What is the diagnosis and what would you do next?<\/jats:p>","DOI":"10.1001\/jama.2025.6076","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T11:30:55Z","timestamp":1748518255000},"page":"532","source":"Crossref","is-referenced-by-count":0,"title":["A Woman With Headache, Fatigue, and Aphasia"],"prefix":"10.1001","volume":"334","author":[{"given":"Natalie S.","family":"Rosen","sequence":"first","affiliation":[{"name":"Herbert Irving Comprehensive Cancer Center and Columbia University Irving Medical Center, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Hughes","sequence":"additional","affiliation":[{"name":"Herbert Irving Comprehensive Cancer Center and Columbia University Irving Medical Center, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Eisenberger","sequence":"additional","affiliation":[{"name":"Herbert Irving Comprehensive Cancer Center and Columbia University Irving Medical Center, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"key":"jcg250002r1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.3807","article-title":"Immune thrombotic thrombocytopenic purpura: a review.","author":"Pishko","year":"2025","journal-title":"JAMA"},{"issue":"10","key":"jcg250002r2","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1111\/trf.14804","article-title":"ADAMTS13: origins, applications, and prospects.","volume":"58","author":"Plautz","year":"2018","journal-title":"Transfusion"},{"issue":"4","key":"jcg250002r3","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1016\/S2352-3026(17)30026-1","article-title":"Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies.","volume":"4","author":"Bendapudi","year":"2017","journal-title":"Lancet Haematol"},{"issue":"10","key":"jcg250002r4","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1111\/jth.15010","article-title":"ISTH guidelines for treatment of thrombotic thrombocytopenic purpura.","volume":"18","author":"Zheng","year":"2020","journal-title":"J Thromb Haemost"},{"key":"jcg250002r5","doi-asserted-by":"publisher","DOI":"10.1177\/1076029618825309","article-title":"Comparison of the long-term remission of rituximab and conventional treatment for acquired thrombotic thrombocytopenic purpura.","volume":"25","author":"Owattanapanich","year":"2019","journal-title":"Clin Appl Thromb Hemost"},{"issue":"6","key":"jcg250002r6","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1182\/blood.2020008021","article-title":"A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP.","volume":"137","author":"Coppo","year":"2021","journal-title":"Blood"},{"issue":"4","key":"jcg250002r7","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura.","volume":"380","author":"Scully","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"jcg250002r8","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1182\/bloodadvances.2022008443","article-title":"Adding caplacizumab to standard of care in thrombotic thrombocytopenic purpura.","volume":"7","author":"Djulbegovic","year":"2023","journal-title":"Blood Adv"},{"issue":"7","key":"jcg250002r9","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1182\/blood.2020006052","article-title":"Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura.","volume":"137","author":"Goshua","year":"2021","journal-title":"Blood"},{"issue":"14","key":"jcg250002r10","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1182\/blood.2020009150","article-title":"Redefining outcomes in immune TTP.","volume":"137","author":"Cuker","year":"2021","journal-title":"Blood"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2834700\/jama_rosen_2025_cg_250002_1753989347.80852.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T15:16:33Z","timestamp":1755011793000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2834700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2025.6076","relation":{},"ISSN":["0098-7484"],"issn-type":[{"type":"print","value":"0098-7484"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}